Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.